Chad M. Robins - 26 Nov 2025 Form 4 Insider Report for Adaptive Biotechnologies Corp (ADPT)

Role
CEO and Chairman, Director
Signature
/s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact
Issuer symbol
ADPT
Transactions as of
26 Nov 2025
Net transactions value
-$3,070,747
Form type
4
Filing time
01 Dec 2025, 19:27:35 UTC
Previous filing
12 Nov 2025
Next filing
07 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
ROBINS CHAD M CEO and Chairman, Director C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE /s/ Chad M. Robins by Kyle Piskel, Attorney-in-Fact 01 Dec 2025 0001780649

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ADPT Common Stock Sale $703,284 -35,736 -1.2% $19.68 2,834,239 26 Nov 2025 Direct F1, F2
transaction ADPT Common Stock Sale $2,367,462 -124,998 -4.4% $18.94 2,709,241 01 Dec 2025 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2025.
F2 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.43 to $20.29, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
F3 The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.78 to $19.20, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.